| Date Filed | Type | Description |
| 10/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/02/2023 |
RW WD
| Form RW WD - Withdrawal of Registration Withdrawal Request: |
| 10/02/2023 |
RW
| Form RW - Registration Withdrawal Request: |
| 09/28/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 09/28/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 09/28/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 09/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 09/28/2023 |
10-K
| Annual Report for the period ended June 30, 2023 |
| 08/21/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 07/17/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Renalytix plc Issue of Shares LONDON and SALT LAKE CITY – July 17, 2023 - Renalytix plc , announces the repayment of $1.06 million of the Company’s convertible bond, further details of which were announced on 31 March 2022. The repayment is being made through the issue of 526,211 American Depositary Shares . After settlement of the repayment, the principal remaining under the convertible bond will be reduced by $1.06 million to $15.90 million. 1,052,422 new ordinary shares of £0.0025 each in the capital of the Company will be issued to settle the conversion of 526,211 ADSs, with each ADS representing two Ordinary Shares. An application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 1,052,422 new ..." |
|
| 07/11/2023 |
4
| MCLAIN THOMAS H (President) has filed a Form 4 on Renalytix plc|
Txns:
| Granted 200,000 options to buy
@ $0 |
|
| 07/07/2023 |
4
| Donovan Michael J. (Chief Medical Officer) has filed a Form 4 on Renalytix plc|
Txns:
| Granted 85,731 options to buy
@ $0 |
|
| 07/07/2023 |
4
| Coste Catherine (Director) has filed a Form 4 on Renalytix plc|
Txns:
| Granted 190,000 options to buy
@ $0 |
|
| 07/07/2023 |
4
| McCullough James Renwick (CEO) has filed a Form 4 on Renalytix plc|
Txns:
| Granted 875,017 options to buy
@ $0 |
|
| 07/07/2023 |
4
| MCLAIN THOMAS H (President) has filed a Form 4 on Renalytix plc|
Txns:
| Granted 394,486 options to buy
@ $0 |
|
| 07/07/2023 |
4
| Fleming Fergus (Chief Technical Officer) has filed a Form 4 on Renalytix plc|
Txns:
| Granted 352,902 options to buy
@ $0 |
|
| 07/07/2023 |
4
| Sterling O. James (CFO) has filed a Form 4 on Renalytix plc|
Txns:
| Granted 575,160 options to buy
@ $0 |
|
| 07/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/03/2023 |
3
| Scannell Timothy J (Director) has filed a Form 3 on Renalytix plc |
| 07/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/03/2023 |
3
| MILLS CHRISTOPHER (10% Owner) has filed a Form 3 on Renalytix plc |
| 07/03/2023 |
3
| MCLAIN THOMAS H (President) has filed a Form 3 on Renalytix plc |
| 07/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/03/2023 |
3
| LEVANGIE DANIEL J (Director) has filed a Form 3 on Renalytix plc |
| 07/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/03/2023 |
8-K
| Appointed a new director |
| 07/03/2023 |
3
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (10% Owner) has filed a Form 3 on Renalytix plc |
|